# BioVeda Capital

> BioVeda Capital is a VC fund backing Health Care and Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Singapore, Singapore
- Total investments: 7
- Last investment: Feb 2017
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company-beta/137560/
- Website: http://www.biovedavc.com

BioVeda Capital is a VC fund in Singapore focused on Health Care and Biotechnology. BioVeda is a Singapore based firm. They invest in companies in the healthcare sector with leading market positions, proprietary technologies, and outstanding scientific and management talent. They are a crucial business and scientific bridge between companies in the East and West, linking business and technology between two very diverse markets.

## Contacts

5 contacts available for BioVeda Capital. Shizune tracks 3 team members at BioVeda Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bioveda-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $6.7M–$34M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Biotechnology | 3 | 43% |
| Medical | 2 | 29% |
| Fitness | 1 | 14% |
| Internet | 1 | 14% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 71% |
| Series A | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Singapore | 3 | 43% |
| United States | 3 | 43% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Damien Lim | General Partner & Founder | 0 | https://shizune.co/investors/profile/damien-lim-0e7f |
| Zhi Yang | Founder & Partner | 0 | https://shizune.co/investors/profile/zhi-yang-d3c0 |
| Zhi Yang | Founder & Partner | 6 | https://shizune.co/investors/profile/zhi-yang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sensely | Sensely is a developer of avatar and chatbot-based platform designed to assist insurance plan members and patients. The company's platform leverages conversational interfaces and provides virtual assistant solutions to insurance companies, pharmaceutical clients, and hospital systems worldwide, enabling enterprises to converse with theirmembers in an entirely new way, combining the empathy of human conversation with the efficiency and scalability of the technology. | $8M | Series B | Feb 14, 2017 |  |
| CXA Group | From a modest start in 2013, when they had just three Fortune 500 clients, CXA has grown to become Asia’s leading Insurtech start-up - affirmed by over 600 clients and backed by a group of astute investors who understand the value and transformative potential of CXA’s groundbreaking platform.Employees are now able to proactively manage theirhealth by choosing the best-suited insurance, wellness and disease management offerings while employers are able to view aggregated health and claims analytics of their workforce to prioritise interventions that reduce costs and improve workplace health, productivity and employee engagement. | $8M | Series A | Jan 09, 2015 |  |
| ASLAN Pharmaceuticals | ASLAN is an Asia enabled pharmaceutical company that develops novel medicines for global markets. | $22M | Series B | Oct 10, 2013 |  |
| Biolidics | Biolidics is a medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring. | $6.7M | Series B | Mar 13, 2013 |  |
| Idun Pharmaceuticals | IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected withHepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc. | $27M | Series B | Jun 15, 2004 |  |
| Idun Pharmaceuticals | IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected withHepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc. |  | Series A | Dec 09, 2002 |  |
| Renovis | Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain. | $34.3M | Series B | Jan 10, 2002 |  |

7 of 7 investments shown.

## Co-investors
- [Hambrecht & Quist Capital Management](https://shizune.co/investors/profile/hambrecht-quist-capital-management) — VC Fund, 2 deals together
- [RBC](https://shizune.co/investors/profile/rbc) — VC Fund, 2 deals together
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 2 deals together
- [Ventana Capital Management](https://shizune.co/investors/profile/ventana-capital-management) — VC Fund, 2 deals together
- [Aberdare Ventures](https://shizune.co/investors/profile/aberdare-ventures) — VC Fund, 1 deal together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Seeds Capital](https://shizune.co/investors/profile/seeds-capital) — VC Fund
- [Wavemaker Ventures](https://shizune.co/investors/profile/wavemaker-partners) — VC Fund

## Featured in investor lists
- [Wellness Investors in Singapore](https://shizune.co/investors/wellness-investors-singapore)
- [Wellness VC Funds in Singapore](https://shizune.co/investors/wellness-vc-funds-singapore)
- [Fitness Investors in Singapore](https://shizune.co/investors/fitness-investors-singapore)
- [Fitness VC Funds in Singapore](https://shizune.co/investors/fitness-vc-funds-singapore)
- [Sports VC Funds in Singapore](https://shizune.co/investors/sports-vc-funds-singapore)

## FAQ

### What does BioVeda Capital invest in?

BioVeda Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is BioVeda Capital's check size?

BioVeda Capital typically joins rounds of $6.7M–$34M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BioVeda Capital participates in.

### How do I contact BioVeda Capital?

Public channels for BioVeda Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BioVeda Capital?

The team at BioVeda Capital includes Damien Lim (General Partner & Founder), Zhi Yang (Founder & Partner) and Zhi Yang (Founder & Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co